<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248650</url>
  </required_header>
  <id_info>
    <org_study_id>TRK-820_HD_I_2008</org_study_id>
    <nct_id>NCT01248650</nct_id>
  </id_info>
  <brief_title>Safety Study of TRK-820 for Patient With Hemodialysis</brief_title>
  <acronym>TRK-820</acronym>
  <official_title>A Clinical Study to Investigate Pharmacokinetics and Safety of Single-Dose TRK-820 Soft Capsule in Patient With Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe pharmacokinetics and safety of nalfurafine&#xD;
      hydrochloride in patients receiving hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>TRK-820 5 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalfurafine hydrochloride</intervention_name>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
    <arm_group_label>TRK-820 5 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic renal failure who receive dialysis three times a week on a&#xD;
             regular basis and do not expect an important change in treatment nor a rapid change in&#xD;
             conditions&#xD;
&#xD;
          -  Patients aged 20 years or older&#xD;
&#xD;
          -  Patients whose post-dialysis BMI measured at the nearest time before the singing day&#xD;
             is in the range of 70 ~ 130 %&#xD;
&#xD;
          -  Patients who can understand and follow instructions and participate in the study&#xD;
             during the entire study period&#xD;
&#xD;
          -  Patients who signed the informed consent form before participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have confirmed malignant tumor&#xD;
&#xD;
          -  Patients with cognitive impairment including depression, schizophrenia and dementia&#xD;
&#xD;
          -  Patients with hepatic cirrhosis as a complication&#xD;
&#xD;
          -  Patients with drug allergy to opioids&#xD;
&#xD;
          -  Patients with drug dependency or allergic disease (including skin response to UV&#xD;
             radiation)&#xD;
&#xD;
          -  Patients who participated in other study and received the investigational drug within&#xD;
             1 month before the signing day&#xD;
&#xD;
          -  Patients who participated in other TRK-820 study within 4 weeks before the signing day&#xD;
&#xD;
          -  Pregnant or lactating women or premenopausal women of childbearing potential who do&#xD;
             not conduct contraception&#xD;
&#xD;
          -  Patients who received any of the following drugs within 2 weeks before Day 1&#xD;
&#xD;
               1. Azole antifungal agents&#xD;
&#xD;
                    1. Ketoconazole&#xD;
&#xD;
                    2. Fluconazole&#xD;
&#xD;
                    3. Itraconazole&#xD;
&#xD;
                    4. Clotrimazole&#xD;
&#xD;
               2. Macrolide antibiotics&#xD;
&#xD;
                    1. Erythromycin&#xD;
&#xD;
                    2. Midecamycin&#xD;
&#xD;
                    3. Josamycin&#xD;
&#xD;
                    4. Roxithromycin&#xD;
&#xD;
                    5. Clarithromycin&#xD;
&#xD;
                    6. Triacetyloleandomycin&#xD;
&#xD;
               3. Ritonavir&#xD;
&#xD;
               4. Cyclosporine&#xD;
&#xD;
               5. Nifedipine&#xD;
&#xD;
               6. Cimetidine&#xD;
&#xD;
               7. Amiodarone&#xD;
&#xD;
          -  Patients who had the following drinks and foods within 2 weeks before Day 1&#xD;
&#xD;
               1. Foods and drinks containing grape fruit juice&#xD;
&#xD;
               2. Food and drinks containing St. John's wort&#xD;
&#xD;
          -  Patients who participated in other clinical study during the period between the&#xD;
             singing day and hospitalization (Day 1)&#xD;
&#xD;
          -  Patients who smoked and drank from three months before the signing day&#xD;
&#xD;
          -  Patients who are ineligible for the clinical study for other reasons at the&#xD;
             investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Huh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>November 24, 2010</last_update_submitted>
  <last_update_submitted_qc>November 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hogan Park</name_title>
    <organization>SK Chemicals Co.,Ltd.</organization>
  </responsible_party>
  <keyword>Safety evaluation</keyword>
  <keyword>Pharmacokinetic analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

